Adjuvant Short-Course Trastuzumab in Breast Cancer

Taha Sethjiwala,Manikandan Dhanushkodi,Venkatraman Radhakrishnan,Jayachandran Perumal Kalaiarasi,Nikita Mehra,Archit Joshi,Arun Kumar Rajan,Gangothri Selvarajan,Balasubramanian Ananthi,Priya Iyer,Geetha Senguttuvan,Bharathi Srilatha,Rama Ranganathan,Shirley Sundersingh,Arvind Krishnamurthy,Sridevi Velusamy,Hemanth Raj,Selvaluxmy Ganesarajah,Tenali Gnana Sagar,Trivadi S. Ganesan

Adjuvant Short-Course Trastuzumab in Breast Cancer

2019

Introduction The standard duration of adjuvant trastuzumab is 1 year. But the decision to use for 1 year was chosen arbitrarily in clinical trials. Many patients from developing countries like India cannot afford 1 year of adjuvant trastuzumab.

Keywords:

Clinical trial
Trastuzumab
Breast cancer
Oncology
Adjuvant
Short course
Internal medicine
Medicine
Surgical oncology
Cohort
Historical Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations